Recent advances in light sources, detectors and other optical imaging technologies coupled with the development of novel optical contrast agents have enabled real-time, high resolution, in vivo monitoring of molecular targets. Noninvasive monitoring of molecular targets is particularly relevant to photodynamic therapy (PDT), including the delivery of photosensitizer in the treatment site and monitoring of molecular and physiological changes following treatment. Our lab has developed optical imaging technologies to investigate these various aspects of photodynamic therapy (PDT). We used a laser scanning confocal microscope to monitor the pharmacokinetics of various photosensitizers in in vitro as well as ex vivo samples, and developed an intravital fluorescence microscope to monitor photosensitizer delivery in vivo in small animals. A molecular specific contrast agent that targets the vascular endothelial growth factor (VEGF) was developed to monitor the changes in the protein expression following PDT. We were then able to study the physiological changes due to post-treatment VEGF upregulation by quantifying vascular permeability with in vivo imaging.

Date Published: 10 February 2006
PDF: 7 pages
Proc. SPIE 6097, Optical Molecular Probes for Biomedical Applications, 609701 (10 February 2006); doi: 10.1117/12.649844

Published in SPIE Proceedings Vol. 6097:
Optical Molecular Probes for Biomedical Applications
Samuel I. Achilefu; Darryl J. Bornhop; Ramesh Raghavachari, Editor(s)